On July 15, Medtronic rose 3.08% in regular trading, trading at $81.69/share, with turnover of $173 million. The rebound follows a 3.53% decline in the prior session when the broader healthcare equipment sector came under significant pressure.

On the news front, multiple institutions recently raised their price targets on Medtronic. Baird adjusted its target from $85 to $91 while maintaining a Neutral rating, and BTIG raised its target from $90 to $91 while maintaining a Buy rating. According to FactSet, the analyst consensus rating on Medtronic is Overweight, with an average price target of $96.12, implying meaningful upside from the current share price.

Additionally, S&P recently revised Medtronic's outlook to positive, and Leerink noted that a September RNL coding review could represent a tailwind for the company. Medtronic reported its strongest annual revenue growth in a decade for fiscal 2026 and continues to advance its Hugo robotic surgery platform and cardiac ablation portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)